Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020 Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020
View original post here:
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness
Resource hub streamlines and simplifies application process for clinical trials within EU Resource hub streamlines and simplifies application process for clinical trials within EU
Visit link:
Parexel Announces Solution for EU Clinical Trials Information System Regulation
Television Legend Montel Williams Joins Isiah Thomas During Live Q&A
Read the rest here:
One World Pharma Releases Investor Presentation
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and answer sessions at the H.C. Wainwright Virtual Precision Oncology Conference on Sept. 24.
View post:
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference
Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases
View original post here:
Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science
LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-65be16b3dce1
Go here to see the original:
Tiziana Life Sciences plc: Publication of Research Note
Orphazyme A/SCompany announcement No. 53/2020 Company Registration No. 32266355
Continue reading here:
New incentive program for the Board of Directors of Orphazyme
BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21, 2020, at 1:40 p.m. EDT.
Original post:
Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Novo Nordisk A/S – Share repurchase programme
Read the original here:
Novo Nordisk A/S – Share repurchase programme
Media Release COPENHAGEN, Denmark and BOTHELL, Wash., 21 September 2020